I.V. ROUNDS: Breaking the link between I.V. therapy and HIT

May 2006 
Volume 36  Number 5
Pages 22 - 22
  PDF Version Available!

HEPARIN, an anticoagulant commonly prescribed to prevent deep vein thrombosis (DVT) and other thrombotic complications, is also widely used to maintain patency of central vascular access devices (CVADs). Because patients exposed to heparin can develop antibodies to it, they're at risk for heparin-induced thrombocytopenia (HIT), a potentially fatal complication.

Currently, HIT related to CVAD maintenance is rare. But as CVAD use continues to increase—between 5 and 7 million are placed in the United States annually—so does the risk of HIT. In this article, I'll review HIT and describe ways to reduce your patient's risk.

Recognizing HIT

The first sign of HIT is a significant drop in platelet count, generally 50% or more, that can't be attributed to another cause and that occurs within 4 to 14 days after the start of heparin therapy. (Remember that patients with CVADs can experience thrombocytopenia for ...

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!

1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.

Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.

Featured Jobs

Benefits of Membership

FREE E-Newsletters
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues

Join our CESaver program to earn up to 100 contact hours for only $34.95
Register Now

Lippincott's NursingCenter.com
Explore a world of online resources

Become a Member